HIF1A and hepatocellular carcinoma: Nonetheless, other studies have focused their attention on the hypoxic response switch from HIF-1α- to HIF-2α-dependent pathways supported by sorafenib and succeeding the upregulation of HIF-2α, which subscribes to the insensitivity of hypoxic HCC cells to the drug25.